The offer by needle and syringe manufacturers to voluntarily cap trade margins at 75 per cent after meeting with the National Pharmaceutical Pricing Authority apparently validates the view that without the actionable threat of price control, the healthcare sector cannot be trusted to self-regulate. “The NPPA advised manufacturers to consider regulating price themselves; otherwise, the … Continue reading Is self-regulation in #medtech doomed to fail?
India's latest healthcare shame is a shoddily-conducted government sterilisation drive that proved fatal for 13 women in rural Chhattisgarh. The tale that unfolded in Bilaspur has more than its share of dystopic elements : unhygienic surgical instruments, tainted drugs and women reportedly herded like cattle (or lured like prey) onto the operating table, surgeries completed … Continue reading Bilaspur, Chikalguda and the dichotomy of Indian public healthcare #indiahealth
Two articles I read recently brought home, once more, the absolute lack of a cohesive national debate on "healthcare for all Indians" which is currently a hot topic in New Delhi. One of the articles observed that the Maharashtra state government had yet to deliver on its very dated promise to provide free medicines to … Continue reading India and universal healthcare : public engagement needed
In granting a compulsory licence to Natco on Bayer's cancer drug Nexavar the patents office has done its job well. It has put a provision in the law meant expressly to balance public good with incentives for innovation to its right use. See Shamnad Basheer's lucid analysis of the order on spicyip. But it is … Continue reading India’s compulsory licence to Natco : follow-up thoughts